文献速递肿瘤 PET/CT核素与放射性配体治疗

靶向蛋白降解联合PET显像揭示宿主PD-L1在决定抗PD-1治疗疗效中的作用

Targeted protein degradation combined with PET imaging reveals the role of host PD-L1 in determining anti-PD-1 therapy efficacy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-06-24

本研究合成基于聚合物的溶酶体靶向嵌合体(LYTACs),可特异性降解肝癌细胞PD-L1而不影响宿主细胞PD-L1,并结合89Zr-αPD-L1/Fab小动物PET显像,在肝癌小鼠模型中发现宿主细胞PD-L1而非肿瘤细胞PD-L1对抗PD-1治疗的抗肿瘤反应起关键作用。

要点

  • PD-L1 LYTAC经ASGPR溶酶体途径特异性降解肝癌细胞PD-L1,不影响宿主细胞PD-L1表达。
  • 全身PD-L1 PET显像联合LYTAC揭示宿主细胞PD-L1对抗PD-1治疗抗肿瘤反应起关键作用。
  • LYTAC联合PET策略有潜力克服基因敲除小鼠模型的局限,实现体内靶蛋白选择性降解。

核心结论

  • LYTAC策略经PET显像增强,有潜力克服基因敲除小鼠模型的局限,为体内靶蛋白选择性降解提供通用方法。
  • 该策略可能显著有助于在活体内研究特定细胞亚群相关蛋白功能的作用与机制。

研究设计与样本

  • 研究合成基于聚合物的溶酶体靶向嵌合体(LYTACs),同时携带PD-L1靶向基序和肝细胞特异性去唾液酸糖蛋白受体(ASGPR)识别元件。
  • 使用PD-L1特异性放射性示踪剂89Zr-αPD-L1/Fab进行小动物PET显像以评估PD-L1表达。
  • 在肝癌小鼠模型中联合LYTAC与全身PD-L1 PET显像开展研究。

主要发现

  • PD-L1 LYTAC平台能够通过ASGPR经溶酶体降解途径特异性降解肝癌细胞表达的PD-L1,而不影响宿主细胞的PD-L1表达。
  • 联合全身PD-L1 PET显像,研究显示在肝癌小鼠模型中,宿主细胞PD-L1而非肿瘤细胞PD-L1对抗PD-1治疗的抗肿瘤反应起关键作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immunohistochemical staining of programmed death-ligand 1 (PD-L1) in tumor biopsies acquired through invasive procedures is routinely employed in clinical practice to identify patients who are most likely to benefit from anti-programmed cell death protein 1 (PD-1) therapy. Nevertheless, PD-L1 expression is observed in various cellular subsets within tumors and their microenvironments, including tumor cells, dendritic cells, and macrophages. The impact of PD-L1 expression across these different cell types on the responsiveness to anti-PD-1 treatment is yet to be fully understood. METHODS: We synthesized polymer-based lysosome-targeting chimeras (LYTACs) that incorporate both PD-L1-targeting motifs and liver cell-specific asialoglycoprotein receptor (ASGPR) recognition elements. Small-animal positron emission tomography (PET) imaging of PD-L1 expression was also conducted using a PD-L1-specific radiotracer 89Zr-αPD-L1/Fab. RESULTS: The PD-L1 LYTAC platform was capable of specifically degrading PD-L1 expressed on liver cancer cells through the lysosomal degradation pathway via ASGPR without impacting the PD-L1 expression on host cells. When coupled with whole-body PD-L1 PET imaging, our studies revealed that host cell PD-L1, rather than tumor cell PD-L1, is pivotal in the antitumor response to anti-PD-1 therapy in a mouse model of liver cancer. CONCLUSION: The LYTAC strategy, enhanced by PET imaging, has the potential to surmount the limitations of knockout mouse models and to provide a versatile approach for the selective degradation of target proteins in vivo. This could significantly aid in the investigation of the roles and mechanisms of protein functions associated with specific cell subsets in living subjects.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Du J, Han S, Zhou H, et al. Targeted protein degradation combined with PET imaging reveals the role of host PD-L1 in determining anti-PD-1 therapy efficacy. Eur J Nucl Med Mol Imaging. 2024. PMID: 38910165. doi:10.1007/s00259-024-06804-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。